Literature DB >> 18452388

Current state and future of joint replacements in the hip and knee.

Kevin Lee1, Stuart B Goodman.   

Abstract

Joint replacements of the hip and knee are among the most clinically successful operations. According to figures compiled by the American Academy of Orthopaedic Surgeons, the number of primary total hip replacements performed in the USA was 220,000 in 2003. This was 38% more than in 1996 and this number is expected to rise to 572,000 (plus another 97,000 revisions) by 2030. The number of primary total knee replacements performed in 2003 was approximately 418,000 and is expected to rise exponentially with the increasing numbers of baby boomers and the aging population. Current research focuses not only on extending implant longevity, but also on improving function to meet the increased demands of today's patients, who are likely to be younger and more active than their predecessors two decades ago. Potential advancements in arthroplasty surgery include new, more wear-resistant bearing surfaces, porous metals to enhance osseointegration and replace lost bone stock, a clearer understanding of the biological processes associated with periprosthetic osteolysis, minimally invasive surgery and computer assisted surgery. Long-term studies are needed to establish the efficacy of these new technologies.

Entities:  

Mesh:

Year:  2008        PMID: 18452388     DOI: 10.1586/17434440.5.3.383

Source DB:  PubMed          Journal:  Expert Rev Med Devices        ISSN: 1743-4440            Impact factor:   3.166


  27 in total

1.  Does lateral release change patellofemoral forces and pressures?: a pilot study.

Authors:  Jeffrey I Peretz; Kim R Driftmier; Douglas L Cerynik; Neil S Kumar; Norman A Johanson
Journal:  Clin Orthop Relat Res       Date:  2011-10-26       Impact factor: 4.176

2.  How much tibial resection is required in total knee arthroplasty?

Authors:  Christoph Schnurr; György Csécsei; Jochen Nessler; Peer Eysel; Dietmar Pierre König
Journal:  Int Orthop       Date:  2010-05-09       Impact factor: 3.075

Review 3.  Mediators of the inflammatory response to joint replacement devices.

Authors:  Neil Cobelli; Brian Scharf; Giovanna M Crisi; John Hardin; Laura Santambrogio
Journal:  Nat Rev Rheumatol       Date:  2011-09-06       Impact factor: 20.543

4.  Cementless revision TKA with bone grafting of osseous defects restores bone stock with a low revision rate at 4 to 10 years.

Authors:  S A Hanna; W J S Aston; N J de Roeck; A Gough-Palmer; D P Powles
Journal:  Clin Orthop Relat Res       Date:  2011-06-16       Impact factor: 4.176

5.  Toll-like receptors-2 and 4 are overexpressed in an experimental model of particle-induced osteolysis.

Authors:  Roberto D Valladares; Christophe Nich; Stefan Zwingenberger; Chenguang Li; Katherine R Swank; Emmanuel Gibon; Allison J Rao; Zhenyu Yao; Stuart B Goodman
Journal:  J Biomed Mater Res A       Date:  2013-10-07       Impact factor: 4.396

Review 6.  Biomaterial strategies for engineering implants for enhanced osseointegration and bone repair.

Authors:  Rachit Agarwal; Andrés J García
Journal:  Adv Drug Deliv Rev       Date:  2015-04-08       Impact factor: 15.470

7.  Osteogenic activity of locally applied small molecule drugs in a rat femur defect model.

Authors:  Jessica A Cottrell; Francis M Vales; Deborah Schachter; Scott Wadsworth; Rama Gundlapalli; Rasesh Kapadia; J Patrick O'Connor
Journal:  J Biomed Biotechnol       Date:  2010-06-16

Review 8.  Interaction of staphylococci with bone.

Authors:  John A Wright; Sean P Nair
Journal:  Int J Med Microbiol       Date:  2009-11-03       Impact factor: 3.473

9.  Brake response time before and after total knee arthroplasty: a prospective cohort study.

Authors:  Michael C Liebensteiner; Michaela Kern; Christian Haid; Conrad Kobel; David Niederseer; Martin Krismer
Journal:  BMC Musculoskelet Disord       Date:  2010-11-18       Impact factor: 2.362

Review 10.  Poly (lactic acid)-based biomaterials for orthopaedic regenerative engineering.

Authors:  Ganesh Narayanan; Varadraj N Vernekar; Emmanuel L Kuyinu; Cato T Laurencin
Journal:  Adv Drug Deliv Rev       Date:  2016-04-25       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.